KROS · CIK 0001664710
What Keros Therapeutics, Inc. told the SEC could break it.
Keros has no products approved for commercial sale and has never generated product-sales revenue, so its 2025 results offer a misleading picture: total revenue of $244.1 million was almost entirely from Takeda ($243.9 million), and its profitability that year was driven by a one-time upfront license payment rather than a recurring business. Its supply chain is a second concentration point — it relies on a single-source contract manufacturer for each of its lead candidates, rinvatercept and elritercept, with no alternative production or disaster-recovery facilities, so a disruption could severely interrupt supply. Its eventual value depends on future clinical and regulatory success, and if its candidates are approved, drug-pricing pressures — the Medicare Drug Price Negotiation Program and EU cost-containment — could cut reimbursement.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- essentially all 2025 revenue from Takeda ($243.9M, one-time-heavy)high
Keros's 2025 revenue ($244.1M total) was almost entirely from Takeda ($243.9M of license + service revenue), and its 2025 profitability was driven by the one-time Takeda upfront payment.
“While we were profitable in the year ended December 31, 2025, this was driven by the one-time upfront payment from our license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda.”
SEC filing →As of 2026
Sole-source dependency
- single-source CMO for each of rinvatercept and elritercepthigh
Keros relies on a single-source CMO for the manufacture of each of rinvatercept and elritercept, and its CMOs have no alternative production plans or disaster-recovery facilities, so a disruption could severely interrupt supply.
“This could be particularly problematic where we rely on a single-source supplier, as is currently the case for the manufacture of each of rinvatercept and elritercept.”
SEC filing →As of 2026
Other disclosures
- no approved products; no product-sales revenue to datemedium
Keros has not progressed any candidate through late-stage trials, has no products approved for commercial sale, and has never generated product-sales revenue, so its value depends on future clinical/regulatory success.
“we have no products approved for commercial sale and we have not generated any revenue from product sales to date.”
SEC filing →As of 2026
Regulatory & policy
- Medicare Drug Price Negotiation & EU price controlsmedium
The Medicare Drug Price Negotiation Program is expected to significantly cut per-unit Medicare reimbursement for selected drugs, and EU/Canada cost-containment pressures pricing for therapeutics like Keros's candidates if approved.
“Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Hansoh Pharmaceutical Group
“Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory. Pursuant to the terms of the Hansoh Agreement, we received a net $18.0 million upfront payment in January 2022.”
Cited →Takeda Pharmaceuticals U.S.A., Inc.
“On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch